Shivalik Rasayan Completes Rs 30.75 Crore Capital Raise

Aggregate capital raised: Rs 30.75 crore; Post-dilution capital: Rs 8.49 crore.

Reader Takeaway: Infusion boosts capital reserves for growth while signaling long-term commitment from promoters and external investors.

What just happened

Shivalik Rasayan Limited has executed a significant capital-raising exercise through a preferential allotment of both equity shares and convertible warrants. As of September 14, 2026, the company issued 2,82,000 equity shares at Rs 250 each, totaling Rs 7.05 crore. Simultaneously, it allotted 9,47,990 fully convertible warrants at the same price, aggregating to Rs 23.70 crore.

Why this matters

The fundraising provides the company with immediate liquidity while ensuring future equity capital through the conversion of warrants. The participation of Growel Remedies Limited, a promoter group entity, highlights confidence in the company's current trajectory. Other key participants include Bishnoi Exports Private Limited and Ginnerup Capital ApS, reflecting diversified investor interest.

What changes now

Following the equity allotment, the company's paid-up equity capital stands at Rs 8.02 crore, divided into 1,60,32,365 shares with a face value of Rs 5 each. Once the warrants are fully converted, the paid-up capital is expected to increase to Rs 8.49 crore, consisting of 1,69,80,355 shares.

Risks to watch

Investors should closely monitor the warrant conversion schedule and the subsequent impact on earnings per share due to the expanded equity base. Any delay in conversion or fluctuations in the broader chemical and pharmaceutical market sentiment could influence price performance.

What to track next

The primary focus for shareholders remains the utilization of the Rs 30.75 crore raised and the timeline for the conversion of the warrants into equity shares, which will determine the final impact on total equity dilution.